Back to News & PR Nordic Life Sciences Interview: Valo Therapeutics CEO Paul Higham Other News News Article Read about what we're doing in Precision Oncology News https://www.precisiononcologynews.com/Reprint-GW22015ValoTherapeutics 15/8/22 Read more News Article Scientific publication: Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in PeptiCRAd cancer vaccine platform ValoTx is pleased to share a new publication in Molecular Therapy Oncolytics (2021 in press) from IVTLab and Valo Therapeutics on PeptiCRAd technology and our proprietary oncolytic adenovirus platform. A link to the paper can be found here Abstract Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules including various cytokines or chemokines. Here, we have developed 10/2/21 Read more News Article Valo Therapeutics Granted USA Patent for PeptiCRAd Technology in Cancer Immunotherapy Helsinki, 24th November, 2020 Valo Therapeutics, the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced that the US Patent Office has granted US Patent No 10,799,568 on 13 October 2020, covering its lead PeptiCRAd platform technology. The patent covers the use of adenoviral vectors having tumor-specific peptides attached to the viral capsid, for stimulating targeted anti-tumor immune responses in cancer patients. Patents for PeptiCRAd technology have been previously granted in Europe (No 3145537) and in 24/11/20 Read more